GLP-1 Red Flags: Warning Signs That Need Immediate Attention
Know the critical warning signs while on GLP-1 medications. Learn when to call your doctor, visit the ER, or stop semaglutide or tirzepatide. Your safety guide for GLP-1 treatment.
More on Monitoring
Emergency: Call 911
If you experience difficulty breathing, swelling of the face/tongue/throat, severe chest pain, or loss of consciousness while on any GLP-1 medication, call 911 immediately.
Go to the ER Immediately
Severe Abdominal Pain Radiating to Back
This could indicate pancreatitis, a rare but serious complication. The pain is typically severe, constant, and worsens after eating. Do not wait -- seek emergency care.
Allergic Reaction Signs
Facial or throat swelling, difficulty breathing, severe rash or hives, rapid heartbeat, or dizziness. Anaphylaxis is rare but life-threatening.
Severe Dehydration
Dark urine or no urination for 12+ hours, extreme dizziness, confusion, rapid heart rate, or fainting. Usually results from persistent vomiting or diarrhea.
Signs of Kidney Injury
Significant decrease in urination, swelling in legs or ankles, nausea with confusion, or flank pain. Dehydration from GI side effects can stress the kidneys.
Call Your Doctor Within 24 Hours
Vomiting That Won't Stop
If you can't keep fluids down for more than 12 hours, contact your provider. Prolonged vomiting leads to dehydration and electrolyte imbalances.
Severe Upper Right Abdominal Pain
Could indicate gallbladder issues (gallstones or cholecystitis). Rapid weight loss increases gallstone risk. Pain may worsen after fatty meals.
Vision Changes
Blurred vision or other visual disturbances can occur, especially in diabetic patients. Rapid blood sugar changes can temporarily affect vision.
Neck Swelling or Lump
While thyroid tumors from GLP-1s have only been seen in animal studies, any neck lump or persistent hoarseness should be evaluated promptly.
How to Stay Safe on GLP-1 Treatment
Prevention Strategies
- Stay well-hydrated (64+ oz daily)
- Follow the dose titration schedule
- Get recommended lab work on schedule
- Keep a symptom diary
Know Your Risk Factors
- History of pancreatitis or gallbladder disease
- Kidney disease or dehydration risk
- Family history of thyroid cancer (MTC)
- Diabetic retinopathy
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. If you are experiencing a medical emergency, call 911. Always consult your healthcare provider about any concerning symptoms.
Frequently Asked Questions
What are the most serious side effects of GLP-1 medications?
The most serious potential side effects include pancreatitis (severe abdominal pain), gallbladder problems, kidney injury from dehydration, severe allergic reactions, and thyroid tumors (risk found in animal studies). These are rare but require immediate medical attention.
Should I go to the ER for severe nausea on semaglutide?
Go to the ER if nausea leads to inability to keep down any fluids for 24+ hours, signs of severe dehydration (dark urine, dizziness, rapid heart rate), or if accompanied by severe abdominal pain. Mild to moderate nausea is common and manageable at home.
Can GLP-1 medications cause pancreatitis?
There is a small increased risk of pancreatitis with GLP-1 medications. Symptoms include severe upper abdominal pain radiating to the back, nausea, vomiting, and tenderness. If you experience these symptoms, stop the medication and seek emergency care immediately.
When should I call my doctor vs. go to the ER?
Call your doctor for: persistent but manageable side effects, no weight loss after 3 months, injection site reactions, or moderate GI symptoms. Go to the ER for: severe abdominal pain, inability to keep fluids down for 24+ hours, signs of allergic reaction, or any symptoms you feel are urgent.
Safe, Monitored GLP-1 Treatment
Compounded semaglutide from $99/mo or tirzepatide from $125/mo with provider oversight.
View Treatment OptionsSources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).